Welcome to our dedicated page for ARDELYX SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ARDELYX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ARDELYX's regulatory disclosures and financial reporting.
Laura A. Williams, listed as Chief Patient Officer and a director of Ardelyx, Inc. (ARDX), reported a non-derivative sale on 08/21/2025. The filing shows 6,261 shares of common stock were sold at $5.9317 per share under code S(1). The sale was executed pursuant to an automatic sell-to-cover tied to the vesting of restricted stock units to cover withholding taxes. After the transaction, Williams is reported to beneficially own 396,322 shares. The Form 4 was signed by an attorney-in-fact on 08/25/2025.
Ardelyx, Inc. insider Justin A. Renz, the company's Chief Financial Officer, reported a sale of 7,037 shares of ARDX common stock on 08/21/2025 at an average price of $5.9317 per share. After the transaction, Mr. Renz beneficially owned 409,052 shares. The filing states the sale was an automatic "sell-to-cover" triggered when restricted stock units vested, executed solely to satisfy withholding tax obligations. The Form 4 was signed by an attorney-in-fact on 08/25/2025.
Michael G. Raab, President & CEO and Director of Ardelyx, Inc. (ARDX), reported a sale of 45,687 shares of common stock on 08/21/2025 at a price of $5.9317 per share. The filing states the sale was an automatic sell-to-cover to satisfy tax withholding upon vesting of restricted stock units. After the transaction, Mr. Raab beneficially owns 1,502,250 shares directly, plus 24,364 shares held in his living trust and 1,000 shares held in trusts for his children. No derivative transactions are reported in this Form 4. The form is signed by an attorney-in-fact and dated 08/25/2025.
Elizabeth A. Grammer, Chief Legal and Administrative Officer of Ardelyx, Inc. (ARDX), reported the disposition of 5,841 shares of the issuer's common stock on 08/21/2025. The sale was executed at $5.9317 per share under code S(1) and is described as an automatic sell-to-cover tied to the vesting of restricted stock units to satisfy withholding taxes. Following the transaction, Ms. Grammer beneficially owned 305,890 shares, held directly. The form is signed by the reporting person on 08/25/2025.
Eric Duane Foster, Chief Commercial Officer of Ardelyx, Inc. (ARDX), reported a routine stock transaction dated 08/21/2025. Pursuant to an automatic sell-to-cover tied to the vesting of restricted stock units, 15,308 shares of Common Stock were sold at an average price of $5.9317 per share to satisfy applicable tax withholding. After the sale, Mr. Foster beneficially owned 301,498 shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Foster on 08/25/2025. No derivatives or other transactions are reported.
Ardelyx, Inc. is reported to have a significant institutional stake held by Janus Henderson Group plc. The filing shows Janus Henderson beneficially owns 15,057,940 shares, representing 6.3% of the outstanding common stock, with shared voting and shared dispositive power over 15,057,940 shares. A related subsidiary, JHIUS, is disclosed as potentially beneficial owner of 14,928,999 shares (6.2%) and, together with JHIUKL and JHIAIFML, is identified as an indirect subsidiary that serves as a registered investment adviser to Managed Portfolios. The filer certifies these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Ardelyx (ARDX) Q2-25 10-Q highlights
Total revenue rose 33% YoY to $97.7 m, driven by 84% growth in IBSRELA sales to $65.0 m. XPHOZAH sales fell 33% to $25.0 m after Medicare moved the drug into the ESRD PPS bundle on 1 Jan 25. Six-month revenue reached $171.8 m (+44%).
Gross margin remained high; cost of goods sold was $12.4 m (12.7% of revenue). Operating expenses climbed 29% to $99.7 m as SG&A spending supporting commercial expansion hit $84.0 m; R&D was $15.7 m. Net loss widened to $19.1 m (-$0.08/sh) versus -$16.5 m (-$0.07/sh) a year earlier; six-month loss totalled $60.2 m.
Balance sheet: cash, equivalents and short-term investments stand at $238.5 m. On 30 Jun 25 Ardelyx drew a new $50 m Term E loan, lifting total debt to $201.4 m; another $100 m is available through 2026. Interest-only payments run to Jul-28, but the blended rate on existing tranches is SOFR + 4–8% plus fees.
Other items: a $5 m milestone from Fosun (China NDA approval) booked in Q1. Non-cash royalty revenue from Kyowa Kirin (Japan) was $1.4 m. The $75 m AstraZeneca termination royalty is now fully amortized. Litigation over CMS bundling of XPHOZAH continues; oral arguments are scheduled for Sep-25.
Liquidity runway is solid, but profitability depends on sustaining IBSRELA momentum and offsetting XPHOZAH reimbursement headwinds.
Ardelyx, Inc. (ARDX) has amended its February 2022 Loan & Security Agreement for the fifth time, securing an immediate $50 million senior secured term loan ("Term E") and gaining access to an additional $100 million of committed capital in two optional $50 million tranches ("Term F" and "Term G").
Key economics include: (1) Term E pricing at 4.00% plus 0.022% plus 1-month SOFR, with a SOFR floor of 4.70%; (2) optional Term F/G pricing at SOFR + 4.95%, floored at 3.50%; (3) interest-only payments until maturity—July 1, 2028 for Term E and July 1, 2030 for Term F/G. The company paid a $250k draw fee for Term E and a $1.0 million facility fee for the incremental loans.
The facility remains collateralized and carries back-end fees of 4.95% (Term E) and 3.45% (Term F/G) of principal, payable upon maturity, acceleration, or prepayment. No changes were disclosed to covenants or security packages.
Investment view: The amendment immediately bolsters liquidity and provides flexible growth or runway capital through 2026, but materially increases secured debt capacity and locks in high floating-rate interest costs. Investors should weigh the near-term cash benefit against potential future leverage and interest-expense drag.